The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines
Open accessAbstract
The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
All About Albumin: Biochemistry, Genetics, and Medical Applications
Peters, T. (1995) · Thammasat University Digital Collections · Cited by 3,372
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Decoding the Patterns of Self and Nonself by the Innate Immune System
Medzhitov, R., & Janeway, C. A. (2002) · Science · doi:10.1126/science.1068883 · Cited by 2,154
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms
Aird, W. C. (2007) · Circulation Research · doi:10.1161/01.res.0000255691.76142.4a · Cited by 1,750
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Phenotypic Heterogeneity of the Endothelium: II. Representative Vascular Beds
Aird, W. C. (2007) · Circulation Research · doi:10.1161/01.res.0000255690.03436.ae · Cited by 1,257
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas
von Maltzahn, G., Park, J.-H., Agrawal, A., Bandaru, N. K., Das, S. K., Sailor, M. J., & Bhatia, S. N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4242 · Cited by 1,051
Self-citationShen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles
Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 985
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Transport of molecules across tumor vasculature
Jain, R. K. (1987) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00047468 · Cited by 866
Tenzer, S., Docter, D., Rosfa, S., Wlodarski, A., Kuharev, J., Rekik, A., Knauer, S. K., Bantz, C., Nawroth, T., Bier, C., et al. (2011) · ACS Nano · doi:10.1021/nn201950e · Cited by 856
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 814
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
The Evolution of the Protein Corona around Nanoparticles: A Test Study
Lundqvist, M., Stigler, J., Cedervall, T., Berggård, T., Flanagan, M. B., Lynch, I., Elia, G., & Dawson, K. (2011) · ACS Nano · doi:10.1021/nn202458g · Cited by 752
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Choi, C. H. J., Alabi, C. A., Webster, P., & Davis, M. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914140107 · Cited by 699
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 2×
“Abraxane was approved by the FDA in 2005 for treatment of breast, lung, pancreatic, and small cell lung cancers [62].”
The mononuclear phagocyte system
Hume, D. A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.008 · Cited by 649
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
Benezra, M., Penate-Medina, O., Zanzonico, P. B., Schaer, D., Ow, H., Burns, A., DeStanchina, E., Longo, V., Herz, E., Iyer, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45600 · Cited by 645
Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618
Analysis of anticancer drugs: A review
Nussbaumer, S., Bonnabry, P., Veuthey, J.-L., & Fleury-Souverain, S. (2011) · Talanta · doi:10.1016/j.talanta.2011.08.034 · Cited by 568
Zhang, G., Yang, Z., Lu, W., Zhang, R., Huang, Q., Tian, M., Li, L., Liang, D., & Li, C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.038 · Cited by 563
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
Yuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., & Jain, R. K. (1994) · PubMed · Cited by 463
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Yang, X., Hong, H., Grailer, J. J., Rowland, I. J., Javadi, A., Hurley, S. A., Xiao, Y., Yang, Y., Zhang, Y., Nickles, R. J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.006 · Cited by 436
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Melancon, M. P., Lu, W., Yang, Z., Zhang, R., Cheng, Z., Elliot, A. M., Stafford, J., Olson, T., Zhang, J. Z., & Li, C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0016 · Cited by 392
Tumor targeting by an aptamer.
Hicke, B. J., Stephens, A. W., Gould, T. A., Chang, Y.-F., Lynott, C. K., Heil, J., Borkowski, S., Hilger, C. S., Cook, G., Warren, S., et al. (2006) · PubMed · Cited by 384
How do anti-mitotic drugs kill cancer cells?
Gascoigne, K. E., & Taylor, S. S. (2009) · Journal of Cell Science · doi:10.1242/jcs.039719 · Cited by 327
Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity
Chanda, N., Kattumuri, V., Shukla, R., Zambre, A., Katti, K., Upendran, A., Kulkarni, R. R., Kan, P., Fent, G. M., Casteel, S. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002143107 · Cited by 321
Hannon, M. J. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779122243 · Cited by 313
Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.002 · Cited by 296
Maturing antibody–drug conjugate pipeline hits 30
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4009 · Cited by 295
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00027-6 · Cited by 271
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris III, H. A., LoRusso, P. M., Yi, J.-H., Saad, O., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1817-3 · Cited by 262
Gelation of liposome interior A novel method for drug encapsulation
Lasic, D. D., Frederik, P. M., Stuart, M. C. A., Barenholz, Y., & McIntosh, T. J. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80947-f · Cited by 261
Current status of the molecular mechanisms of anticancer drug-induced apoptosis
Kim, R., Tanabe, K., Uchida, Y., Emi, M., Inoue, H., & Toge, T. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0522-7 · Cited by 253
Austin, C. D., Wen, X., Gazzard, L., Nelson, C., Scheller, R. H., & Scales, S. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509035102 · Cited by 237
Cleavable linkers in chemical biology
Leriche, G., Chisholm, L., & Wagner, A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.048 · Cited by 237
Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003723 · Cited by 220
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., & Gabizon, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990701)86:1<72::aid-cncr12>3.0.co;2-1 · Cited by 213
Hong, H., Zhang, Y., Engle, J. W., Nayak, T. R., Theuer, C. P., Nickles, R. J., Barnhart, T. E., & Cai, W. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.031 · Cited by 204
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Cianfrocca, M., Lee, S., Von Roenn, J., Tulpule, A., Dezube, B. J., Aboulafia, D. M., Ambinder, R. F., Lee, J. Y., Krown, S. E., & Sparano, J. A. (2010) · Cancer · doi:10.1002/cncr.25362 · Cited by 173
Image-Guided Breast Tumor Therapy Using a Small Interfering RNA Nanodrug
Kumar, M., Yigit, M., Dai, G., Moore, A., & Medarova, Z. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2070 · Cited by 164
Rossin, R., Pan, D., Qi, K., Turner, J. L., Sun, X., Wooley, K. L., & Welch, M. J. (2005) · PubMed · Cited by 161
Tumor Models in Cancer Research
(2011) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0 · Cited by 158
Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer
Rose, P. G. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-205 · Cited by 158
Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review
Sassoon, I., & Blanc, V. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_1 · Cited by 157
Linker Technologies for Antibody–Drug Conjugates
Nolting, B. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_5 · Cited by 154
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 152
Sarris, A. H., Hagemeister, F. B., Romaguera, J. E., Rodríguez, M., McLaughlin, P. J., Tsimberidou, A. M., Medeiros, L. J., Samuels, B. I., Pate, O., Oholendt, M. S., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008348010437 · Cited by 143
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
Mross, K. B., Niemann, B., Massing, U., Drevs, J., Unger, C., Bhamra, R. K., & Swenson, C. E. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0825-y · Cited by 137
Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*
Skubitz, K. M. (2003) · Cancer Investigation · doi:10.1081/cnv-120016412 · Cited by 122
Differential distribution of free and bound glutathione and cyst(e)ine in human blood
Mills, B. J., & Lang, C. A. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00241-9 · Cited by 120
Chattopadhyay, N., Fonge, H., Cai, Z., Scollard, D. A., Lechtman, E., Done, S. J., Pignol, J., & Reilly, R. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300016p · Cited by 115
NanoFerrite Particle Based Radioimmunonanoparticles: Binding Affinity and In Vivo Pharmacokinetics
Natarajan, A., Gruettner, C., Ivkov, R., DeNardo, G. L., Mirick, G. R., Yuan, A., Foreman, A. R., & DeNardo, S. J. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800015n · Cited by 110
Gustafson, D. L., Rastatter, J. C., Colombo, T., & Long, M. E. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10161 · Cited by 102
Antibody Drug Conjugates as Cancer Therapeutics
Trail, P. A. (2013) · Antibodies · doi:10.3390/antib2010113 · Cited by 97
Paszko, E., & Senge, M. O. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803833362 · Cited by 96
Karmani, L., Labar, D., Valembois, V., Bouchat, V., Nagaswaran, P. G., Bol, A., Gillart, J., Levêque, P., Bouzin, C., Bonifazi, D., et al. (2013) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1539 · Cited by 94
Cornelissen, B. T., Able, S., Kersemans, V., Waghorn, P. A., Myhra, S., Jurkschat, K., Crossley, A., & Vallis, K. A. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.054 · Cited by 85
Stinchcombe, T. E., Socinski, M. A., Walko, C. M., O’Neil, B. H., Collichio, F. A., Ivanova, A., Mu, H., Hawkins, M., Goldberg, R. M., Lindley, C. M., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0423-x · Cited by 79
A comparison of theoretical methods of calculation of partition coefficients for selected drugs.
Pyka, A., Babuśka, M., & Zachariasz, M. (2006) · PubMed · Cited by 70
Bellott, R., Auvrignon, A., Leblanc, T. M., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000206 · Cited by 65
Brentuximab vedotin: An anti-CD30 antibody–drug conjugate
Bradley, A. M., Devine, M., & DeRemer, D. L. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110608 · Cited by 51
Ando, M., Yonemori, K., Katsumata, N., Shimizu, C., Hirata, T., Yamamoto, H., Hashimoto, K., Yunokawa, M., Tamura, K., & Fujiwara, Y. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1726-5 · Cited by 41
Lim, E., Kim, B., Choi, Y., Ro, Y., Cho, E.-J., Lee, J. H., Ryu, S. H., Suh, J., Haam, S., & Huh, Y. (2013) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34678 · Cited by 40
Quantitative characterization of the lipid encapsulation of quantum dots for biomedical applications
Galloway, J. F., Winter, A., Lee, K. H., Park, J. H., Dvoracek, C. M., Devreotes, P. N., & Searson, P. C. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.12.002 · Cited by 30
Self-citationChemical and Physical Modifications of Biomaterial Surfaces to Control Adhesion of Cells
Groth, T., Liu, Z.-M., Niepel, M. S., Peschel, D., Kirchhof, K., Altankov, G., & Faucheux, N. (2010) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-90-481-8790-4_13 · Cited by 16
Human Tumor Xenograft Efficacy Models
Liu, M., & Hicklin, D. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_5 · Cited by 14
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine
Simon‐Yarza, T., Mielcarek, A., Couvreur, P., & Serre, C. (2018) · Advanced Materials · doi:10.1002/adma.201707365 · Cited by 648
Metadata
- Authors
- Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 187
- Pages
- 133-144
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2146205672
- Cited by
- 527
- References
- 110
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.